Mallinckrodt SA de CV

Keenova and Par Health are two separate companies that operate independently after a merger between Mallinckrodt and Endo in 2025. Keenova Therapeutics focuses on developing treatments for rare, stigmatized, or unaddressed conditions, with areas of focus including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. Par Health, on the other hand, is a pharmaceutical company that develops high-quality generics, sterile injectables, and active pharmaceutical ingredients (APIs), with a robust manufacturing network in the US. Together, the two companies aim to serve patients and customers with a range of pharmaceutical products and therapies.